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Abstract
The flexibility of the epigenome has generated an enticing argument to explore its reversion through pharmacological
treatments as a strategy to ameliorate disease phenotypes. All three families of epigenetic proteins—readers, writers,
and erasers—are druggable targets that can be addressed through small-molecule inhibitors. At present, a few drugs
targeting epigenetic enzymes as well as analogues of epigenetic modifications have been introduced into the clinic
use (e.g. to treat haematological malignancies), and a wide range of epigenetic-based drugs are undergoing clinical
trials. Here, we describe the timeline of epigenetic drug discovery and development beginning with the early design
based solely on phenotypic observations to the state-of-the-art rational epigenetic drug discovery using validated
targets. Finally, we will highlight some of the major aspects that need further research and discuss the challenges that
need to be overcome to implement epigenetic drug discovery into clinical management of human disorders. To turn
into reality, researchers from various disciplines (chemists, biologists, clinicians) need to work together to optimise the
drug engineering, read-out assays, and clinical trial design.
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Background
Seventy-five years ago, the British biologist Conrad
Waddington coined the term epigenetics to describe the
mechanisms by which an organism stably adapts its
phenotype to the environment [1]. Over time, this led to
the classical definition (Table 1) of epigenetics as a
phenotypic variation that does not originate from an
underlying change in the organism’s genotype. Such epi-
genetic modulation of the genome is self-evident for
multicellular eukaryotic organisms. For example, al-
though the cells in our body carry an identical genome,
they are clearly able to differentiate and produce higher
order tissues and organs distinct from one another. This
must be achieved by cell-specific variations in gene ex-
pression and, although several definitions of epigenetics
are being proposed [2], operationally, we can define epi-
genetics as the structural adaptation of chromosomal
regions so as to register, signal, or perpetuate altered ac-
tivity states.
At the molecular level, epigenetics involves a highly com-
plex and dynamically reversible set of structural modifica-
tions within the nucleic acids and histone proteins that
constitute the nucleosome [3]. These chemical alterations are
catalysed by enzymes that are often referred to as ‘writers’
and result in the addition to DNA or histones of entities ran-
ging in size from a single methyl group (molecular weight of
15Da) to proteins such as ubiquitin (molecular weight of 8.5
kDa). Such molecular decorations not only directly influence
the affinity between DNA and histone proteins but also re-
cruit partner macromolecules such as non-coding RNAs
(ncRNAs) and chromatin remodellers. The binding interac-
tions are controlled through so-called ‘reader’ domains that
recognise specific features within the chemically modified
nucleic acids and proteins. Finally, to ensure the process is
reversible, a series of ‘eraser’ enzymes catalyses the removal
of the written information ensuring a dynamic character [3].
Epigenetics is a necessary and essential component of
an organism’s normal development and its responsive-
ness to environmental cues [4]. Nevertheless, it can suf-
fer from dysregulation and there are three major
scenarios whereby epigenetics is a significant contributor
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to the origin and progression of human diseases. Firstly,
increasing insights are obtained on disease-associated
epigenetic abnormalities (both heritable as well as envir-
onmentally induced) [5]. These localised differences in
epigenetic states between normal and disease tissues can
be exploited as disease biomarkers with diagnosis and/or
prognosis potential. Tests to study the DNA methylation
of specific genes (e.g. septin 9, vimentin or BMP3,
NDRG4) in non-invasive tissues have been FDA-
approved for early colorectal cancer screening pro-
grammes [6, 7]. A plethora of studies identifying epigen-
etic differences in non-tumoural diseases are being
conducted; however, they have not yet been developed
as commercially available devices and are under clinical
trial evaluation or preclinical states. As an example, the
diagnostic value of DNA methylation at the BDNF pro-
moter is being tested in clinical trials for the treatment
of major depression or autisms [8].
Secondly, the patterns of activity or expression levels
of an epigenetic protein can be substantially different in
a disease state compared with normal physiology. For
example, DNA methyltransferases (DNMTs) are respon-
sible for writing the C5-methylation of CpG dinucleotide
sequences [4]. In cancer cells, the pattern of methylation
shifts from predominantly non-coding DNA to promoter
regions within the genome [4]. Since DNA methylation
at promoter regions is generally associated with gene si-
lencing, the consequence is the shutdown of pathways,
e.g. DNA repair that would normally help prevent
tumour cell proliferation. With respect to disturbed
transcription levels, the histone-modifying epigenetic
eraser histone deacetylases (HDACs), for example, are
found to be highly expressed in many cancers and their
increased activity is linked to gene repression [9].
Thirdly, somatic mutations involving epigenetic proteins
with resulting gain-of-function or loss-of-function that
predispose towards disease have been identified [10]. For
example, genetic mutations of the DNA methylation
machinery are prominent features of many tumours, espe-
cially haematological malignancies (i.e. targeting gain-of-
function mutations in DNMT3A in lymphomas are under
Phase II clinical trials) [11]. Activating mutations of
epigenome-modifying enzymes are really interesting
because they open a therapy option based on their inhib-
ition. In this regard, mixed-lineage leukaemia (MLL) is
caused by a translocation of chromosome 11. The result-
ing fusion of the MLL gene promotes recruitment of the
lysine methyltransferase DOT1L to methylate histones at
pro-leukaemia genes and drive aberrant gene transcription
[12]. The targeted inhibition of DOT1L selectively de-
creases proliferation of cancer cells harbouring the trans-
location but not the normal cells [13].
Importantly, all three families of epigenetic proteins—
readers, writers, and erasers—are druggable targets that
can be addressed through small-molecule inhibitors. The
discovery and development of epigenetic drugs are ex-
tensively described throughout this review. Here, we
provide the timeline of epigenetic drug discovery and
discuss some of the many challenges and promises still
ahead of us.
The first wave of epigenetic drugs: from
phenotypic reality to epigenetic dreams
While rational epigenetic drug discovery using validated
targets is now a reality, we should not forget that this
enlightened state of affairs is a recent phenomenon. In-
deed, drug discovery is ultimately based on the demon-
stration of efficacy rather than precise knowledge of the
molecular target. As we shall see, this is how epigenetic
drug discovery evolved and the early (and successful) ef-
forts were based solely on phenotypic observations be-
fore an epigenetic connection was realised.
DNA methyltransferase inhibitors
In the 1940s and 1950s, the nucleoside building blocks
used by Nature to build DNA and RNA became import-
ant lead structures for medicinal chemistry. It was
believed that structurally related analogues would behave
as antimetabolites that interfere with the normal func-
tion of the natural metabolites. Some of these com-
pounds inhibited biosynthesis pathways while others
were sufficiently similar to be incorporated into nucleic
acids and thereby disrupt their function or replication.
Relatively subtle modifications of the pyrimidine nucleo-
base in cytidine have led to drugs such as 5-azacytidine
[14] (5-azaC or azacytidine) and 5-aza-2′-deoxycytidine
[15] (5-aza-dC or decitabine (Fig. 1). Due to their simi-
larity to cytidine, both compounds are recognised by
polymerases and added to the growing chain of nucleic
acids. 5-Aza-dC contains the DNA sugar deoxyribose
and is incorporated into DNA only, while the ribose
sugar in 5-azaC allows incorporation into RNA and
DNA after removal of the 3′OH. Compared with the
natural nucleic acid building blocks, there is only a sin-
gle replacement of carbon (C5 in the pyrimidine ring) by
nitrogen but this has profound biological consequences.
5-azaC was found to have high antibacterial activity with
Table 1 Definitions of epigenetics ranging from classical to the
translational
Classical Alterations in biological phenotype without an underlying
change in genotype
Biological Regulation of eukaryotic gene expression through chromatin
remodelling
Chemical Reversible structural modifications of DNA and histone
proteins
Drug
discovery
Targeting proteins that introduce, recognise, or remove DNA
and histone modifications
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a MIC50 of 250 nM against an E. coli strain and toxic
in mice with a LD50 of 150 mg/kg [16]. The toxicity
was primarily manifested in the bone marrow and
lymphatic system and suggested the compound might
be antileukaemic at a lower dose [16]. Indeed, 5-azaC
was cancerostatic at a single dose of 100 mg/kg in a
mouse lymphoid leukaemia model. The drug was be-
lieved to be a general cytotoxic agent [17] and by
1967 had advanced to clinical trials in Europe. The
rapid progress of 5-azaC from bench to bedside led
to the American National Cancer Institute (NCI) fil-
ing an Investigational New Drug FDA application in
1971. While the clinical trials showed promise in the
treatment of acute myeloid leukaemia (AML), the
data for other haematological or solid tumours was
much less positive [18]. Furthermore, the drug was
accompanied by high toxicity and the FDA rejected
the application. Subsequently, in a landmark 1980
publication, Jones and Taylor provided the first evi-
dence that cytidine analogues modified at the pyrimi-
dine C-5 position such as 5-azaC inhibit DNA
methylation [19]. Importantly, the effect in cells was
achieved at lower doses with prolonged exposure
whereas higher drug concentrations were detrimental.
The novel epigenetic mechanism of action of 5-azaC
and 5-aza-dC (Fig. 1) compared with other clinically
used antimetabolites rekindled interest in their thera-
peutic potential. The most promising application was in
the treatment of myelodysplastic syndrome (MDS), a
bone marrow disorder with a high risk of progressing to
AML that occurs primarily in elderly patients and is
characterised by the production of abnormal blood cells.
New clinical trials were carried out by the biotech com-
panies Pharmion and MGI Pharma with 5-azaC and 5-
aza-dC respectively using lower doses than the earlier
investigations [17, 20]. Both drugs successfully received
Investigational New Drug (IND) status and in 2004 5-
azaC (trade name Vidaza) became the first drug to be
approved by the FDA for all five stages of MDS, followed
suit by 5-aza-dC (trade name Dacogen) in 2006. The
two drugs are currently first-line therapy for MDS when
stem cell therapy is not suitable and are additionally
used to treat chronic myelomonocytic leukaemia
(CMML) and AML [17, 21]. Their success has led to the
Fig. 1 Mechanism of action of azacitidine and decitabine. 5-Azacytidine (compound 1), after metabolic conversion (compound 3) and incorporation into
DNA (compound 4), behaves as a suicide substrate for DNA methyltransferases. The enzyme carries out the usual nucleophilic attack by the active site Cys
residue and methylation by S-adenosyl-L-methionine (SAM) but cannot undergo product release, being trapped instead as the covalent adduct 5,
Decitabine (compound 2), has an identical mechanism of action, except that its metabolism to compound 3 does not require a deoxygenation step
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acquisition of the biotech developers Pharmion by Cel-
gene for $2.9 billion and MGI Pharma by Eisai for $3.9
billion.
Histone deacetylase inhibitors
Vorinostat and romidepsin were the first drugs to be ap-
proved that influence epigenetic post-translational modifica-
tion of histone proteins [22]. Nevertheless, the discovery
effort commenced from phenotypic observations without
knowing that inhibition of HDACs was involved. The vorino-
stat story began in 1971 with observations on the ability of di-
methyl sulfoxide (DMSO) to cause murine erythroleukaemia
cells to differentiate [23]. Ronald Breslow speculated that the
mechanism of action involved DMSO binding to its target
protein through either metal coordination or hydrogen bind-
ing (Fig. 2a). This observation quickly promoted the explor-
ation of a variety of analogues that could make similar
interactions [24, 25]. The process led to the development of
SAHA (suberoylanilide hydroxamic acid) (Fig. 2a). Thus far,
the optimisation process leading from DMSO to SAHA was
based solely on phenotypic screening and in vivo studies [26].
Meanwhile, the availability of purified HDACs was en-
abling identification of the first small-molecule natural
products trichostatin A and trapoxin A that specifically in-
hibit the enzyme (Fig. 2b) [27, 28]. The structural resem-
blance between trichostatin A and SAHA was noticed,
and Breslow soon confirmed that the latter was also a
HDAC inhibitor [29]. X-ray crystallographic studies re-
vealed that the hydroxamic acid in SAHA acts as a metal
chelator that reversibly binds to the zinc cation in the
HDAC active site [29]. SAHA (generic name vorinostat)
entered Phase I clinical trials and showed efficacy in a
number of cancer types [22]. As further work was not
practical in an academic setting, the Breslow set up the
biotech company Aton Pharmaceuticals in 2001. The
company pursued further clinical trials, with the most
promising Phase II results in cutaneous T cell lymphoma
(CTCL), a disorder in which malignant cells migrate to
the skin and form lesions that can further develop into tu-
mours and undergo metastasis. Aton Pharmaceuticals was
acquired by Merck in 2004 for $125 million who com-
pleted Phase IIb trials in CTCL. SAHA, now known by
the trade name Zolinza, received FDA approval in 2006
and is currently a third-line therapy for CTCL [26]. At
present, the clinical applications of vorinostat treatment
have been extended to neurological disorders [8], and,
interestingly, to the reactivation of persistent viral infec-
tion. Actual treatments for HIV-1 patients do not fully
eradicate the virus, since it can be latent in CD4+ reser-
voirs. As the virus latency is mediated, at least in part, by
epigenetic mechanisms [30] Phase I/II clinical trials to test
the effect of vorinostat treatment in the reactivation of
HIV-1 viral latency are being conducted (clinical trial
NCT02707900).
Industrial high-throughput screening was the origin of
romidepsin, the second HDAC inhibitor to receive FDA
approval. At Fujisawa Pharmaceutical, microbial extracts
were tested in an assay based on the reversal of pheno-
type of ras-transformed cancer cells and led to the isola-
tion of the active compound FK228 (Fig. 2c) from a
strain of the bacterium Chromobacterium violaceum
[31]. FK228 displayed high activity in tumour models al-
though the mechanism of action was unknown [31].
Later, despite the lack of structural homology with
known HDAC inhibitors, this was shown to be FK228’s
molecular target [32].
As was the case with vorinostat, Phase I trials with
FK228 were most promising for the treatment of CTCL
[33]. Later, Gloucester Pharmaceuticals carried out piv-
otal Phase II trials with FK228, now named romidepsin
(trade name Istodax), in CTCL and received FDA ap-
proval for this indication in 2009 [34]. The company was
acquired by Celgene in 2010 for $340 million and romi-
depsin received additional approval for a Phase II clinical
trial in peripheral T cell lymphoma (PTCL) in 2011 [35].
While vorinostat is a panHDAC inhibitor that inhibits
all 11 human isoforms with a submicromolar IC50, romi-
depsin displays selectivity between isoforms with potent
nanomolar activity against Class I HDACs (HDAC1, 2,
3, and 8) and a weaker activity against HDAC6.
To summarise, the first four epigenetic drugs were all
discovered through phenotypic assays and the road from
discovery to approval required long timelines (Table 2).
Academic institutions were responsible for the discovery
of three of these compounds. The clinical development
of all four drugs involved biotech companies who were
presumably less risk averse to these experimental targets
than big pharma. Once the drugs were approved, how-
ever, these companies became acquisition targets for lar-
ger organisations. As therapeutics, the DNMT inhibitors
5-azaC and 5-aza-dC have an established and important
role as first-line chemotherapy for the treatment of MDS
with additional usage in CMML and AML. On the other
hand, the HDAC inhibitors vorinostat and romidepsin
occupy a much narrower niche despite their initial
promise in a variety of tumour types in cell-based and
animal models. Their use is restricted to CTCL and
PTCL patients when other treatment options have failed
[5]. Apart from cancer, the use of SAHA is being ex-
plored in neurological disorders, including Huntington’s
disease (Clinical Trial NCT00212316) and amyotrophic
lateral sclerosis (Clinical Trial NCT00107770).
The second wave of epigenetic drugs: from
epigenetic dreams to phenotypic reality
Second-generation DNMT inhibitors
By the early 1990s, assays for DNMT and HDAC activity
were available and potent inhibitors of these enzymes
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had been identified. With this information in hand,
many academic and industrial drug discovery pro-
grammes were initiated that aimed to improve upon the
early leads. In the case of DNMT inhibitors, the
eventually approved 5-azaC and 5-aza-dC have a num-
ber of liabilities. The compounds are not selective for a
specific isoform of DNMT (i.e. DNMT1 vs. DNMT3s)
which might account for some of the side effects.
Fig. 2 First generation of histone deacetylase inhibitors. a Evolution of the HDAC inhibitor vorinostat, with IC50 values indicated for the differentiation
of murine erythroleukaemia cells. From the initial observation on DMSO (compound 6), the more potent simple amide (compound 7) was generated,
although still at a millimolar level. By employing a classic strategy in medicinal chemistry (so-called ‘multivalency’), compound 8 emerged as a better
candidate that entered Phase I/II clinical trials in which partial responses were observed in MDS and AML patients. Attempts to increase the valency
through tri- or tetra-amides were unsuccessful, so the strategy moved to considered hydroxamic acids as an amide isostere. The resulting compound
9 was indeed more potent than 8. The original idea behind multivalency was reconsidered and one hydroxamic acid was replaced by an amide to
pick up hydrophobic interactions. This process led to the new candidate SAHA (compound 10) which was selected for having the right balance
between potency and toxicity. b Natural product inhibitors of histone deacetylases (trichostatin A and trapoxin A). c Romidepsin and its conversion to
the active metabolite. The natural product itself (compound 11) acts as a cell-permeable prodrug that undergoes disulphide bridge reduction within
the cellular environment. In the resulting dithiol (compound 12), one of the thiol groups reversibly coordinates to the active site zinc cation in the
same way as vorinostat through the latter’s hydroxamic acid.
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Importantly, 5-azaC is predominantly incorporated into
RNA rather than DNA, unlike decitabine. Both drugs
have poor bioavailability and are stable only at neutral
pH at low temperature, undergoing hydrolysis in either
aqueous acid or base. Their half-life is further limited by
being accepted as substrates by cytidine deaminase,
which hydrolyses the amino group to an inactive 5-
azauridine.
Several nucleoside analogues that circumvent these
shortcomings have reached clinical development although
they are not yet in clinical practice (Fig. 3). Zebularine in-
hibits both cytidine deaminase and DNMTs and has high
stability in acidic and neutral pH [36]. CP-4200 is an elai-
dic acid ester prodrug of 5-azaC with higher bioavailability
as it is not solely dependent on nucleoside transporters for
drug uptake [37]. SGI-110 (now guadecitabine) is a CpG
dinucleotide mimic containing decitabine instead of deox-
ycytidine; it is not a substrate of cytidine deaminase and
hence not subject to this pathway of metabolic degrad-
ation [38]. Guadecitabine has been tested in a Phase II
clinical trial for the treatment of naïve patients with AML
who are not candidates for intensive chemotherapy [38].
In addition, a number of non-nucleoside small-
molecule leads have been reported as DNMT inhibitors
that are used as preclinical tool compounds against this
target [39]. Among these, a typical strategy is to conceive
analogues of the S-adenosyl-L-methionine (SAM), the
methyl donor [40]. These types of derivatives showed in-
teresting results in several cancer models [41–43] and in
other human diseases such as parasite infection [44].
The DNMT1 inhibitor hydralazine underwent many
clinical trials in the past, both alone and in combina-
tions, and is still in clinical trial (NCT03423810) in poly-
cystic kidney disease patients. In silico models showed
that its DNA demethylating activity can be explained by
the interaction between its nitrogen atoms with residues
Lys162 and Arg240 of the DNA methyltransferase active
site [45]. Similarly, procainamide, anti-arrhythmic agent
with DNMT1 inhibition activity [46], is under clinical
trial against prostate cancer (NCT02103088).
Most recently, bi-substrate analogues have been de-
veloped: DNMTs have two substrates, the cofactor
SAM, donor of the methyl group, and the cytosine,
that will be methylated. By designing analogues of
each substrate and linking them together, it is pos-
sible to obtain potent inhibitors. This strategy re-
sulted in the most potent chemical tools to inhibit
DNMTs to date and they reactivate genes by pro-
moter demethylation in cancer cells [43].
Table 2 Key events in the discovery of the first two waves of
epigenetic drugs
DNA methyltransferase inhibitors
1964 Azacitidine and decitabine synthesis
1967 Azacitidine enters clinical trials
1980 Azacitidine and decitabine identified as DNMT inhibitors
1980 Decitabine enters clinical trials
2004 Azacitidine FDA approval
2006 Decitabine FDA approval
Histone deacetylase inhibitors
1971 DMSO reported as differentiation agent
1976 Bisamide precursor to SAHA (vorinostat) reported as
differentiation agent
1990 Trichostatin A identified as HDAC inhibitor
1990 Romidepsin reported as a natural product
1996 Vorinostat synthesis
1997 Romidepsin enters clinical trials
1998 Vorinostat and romidepsin identified as HDAC inhibitors
2000 Vorinostat enters clinical trials
2006 Vorinostat FDA approval
2009 Romidepsin FDA approval
2014 Belinostat FDA approval
2015 Panobinostat FDA approval
2015 Chidamide China’s FDA approval
Fig. 3 Second-generation DNMT inhibitors. The nucleoside analogue DNMT inhibitors zebularine (compound 13), CP-4200 (compound 14), and
guadecitabine (compound 15) have reached clinical development
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Second-generation HDAC inhibitors
For HDAC inhibitors, the presence of a zinc-binding
warhead is key for high-affinity binding to the active site.
The hydroxamic acid has proven to be the most success-
ful choice and thousands of synthetic HDAC inhibitors
containing this motif have been reported [40]. The early
efforts have primarily concentrated on optimising the
pharmacokinetic properties of vorinostat which suffers
from rapid metabolism and relatively poor bioavailabil-
ity. The spinout company Prolifix focused on trichosta-
tin A and vorinostat analogues containing more rigid
sulfonamide linkers. Ultimately, this would lead to beli-
nostat (Fig. 4a) and the company being acquired by
TopoTarget in 2002. In 2010, the biotech Spectrum
Pharmaceuticals entered into a co-development agree-
ment with TopoTarget including an upfront payment of
$30 million for belinostat. The drug (trade name Beleo-
daq) received FDA approval in 2014 for the treatment of
PTCL [47]. Meanwhile, at Novartis, a reporter assay for
increased expression of the p21Cip1 gene was screened
against their natural product collection and the hits dis-
covered were found to be HDAC inhibitors [48]. A me-
dicinal chemistry effort based on hydroxamic acids
delivered the clinical candidate dacinostat with a similar
cinnamate linker to belinostat. Due to toxicity concerns,
the further development of dacinostat was discontinued
in favour of the second-generation candidate panobino-
stat [49]. In 2015, panobinostat (trade name Farydak) re-
ceived FDA approval for patients with refractory
multiple myeloma that had not responded to previous
treatments [50, 51]. Unlike all the other HDAC inhibi-
tors, panobinostat is unique in being approved outside
CTCL and PTCL for the more widespread and lucrative
indication of multiple myeloma [51]. It is thus far the
only HDAC inhibitor to receive approval within the EU.
More than ten other hydroxamic acid HDAC inhibitors
are currently undergoing clinical trials [52]. Representa-
tive examples include CUDC-101 from Curis (a dual
mechanism of action HDAC and kinase inhibitor), quisi-
nostat from Janssen (an orally bioavailable compound
under investigation for the treatment of solid tumours),
and tefinostat from GlaxoSmithKline (designed for tar-
geted delivery to the liver due to reduced efflux after
liver specific ester hydrolysis) [52].
Despite the number of hydroxamic acid HDAC inhibi-
tors that have reached clinical development, there are
concerns with their pharmacokinetics. Hydroxamic acids
are susceptible to clearance by Phase I conjugation and
metabolism to toxic species and may have off-target ef-
fects due to non-selective metal binding. For these rea-
sons, alternative metal-binding functional groups have
been explored although none is completely satisfactory.
The aforementioned romidepsin remains the only ap-
proved HDAC inhibitor with a thiol zinc-binding group.
Although other related natural products and synthetic
thiol containing HDAC inhibitors with potent activity
have been disclosed, none has progressed to clinical
development.
More successful is the use of ortho-aminoanilides
(benzamides) and the simple example tacedinaline (Fig.
4b) from Pfizer reached Phase II clinical trials before be-
ing discontinued (Clinical Trial NCT00005624). At
Bayer Schering, the benzamide series produced the can-
didate entinostat which was later licenced to Syndax
who are currently performing Phase III trials in combin-
atory chemotherapy in breast cancer (Clinical Trial
NCT03538171). Concurrently, the biotech MethylGene
led to mocetinostat. The company has recently been ac-
quired by Mirati Therapeutics who are investigating
mocetinotat in Phase II trials as a single agent and in
combination therapy in urothelial cancer or non-small
cell lung cancer (Clinical Trials NCT02236195 and
NCT02805660). In China, the biotech Chipscreen Bio-
sciences designed a benzamide series with an alkenyl
linker from which chidamide was selected as the clinical
candidate. In 2015, chidamide (trade name Epidaza) re-
ceived approval from the Chinese FDA for the treatment
of relapsed and refractory PTCL [53]. It is hence the first
‘Made in China’ small-molecule drug for which the en-
tire drug discovery process was carried out within China.
As a class, the benzamides display selectivity against
class I HDACs with chidamide inhibiting HDACs 1, 2, 3,
and the class II HDAC 10 at a nanomolar level [54].
In addition to thiols and benzamides, another zinc-
binding motif that has attracted attention for HDAC in-
hibition is the carboxylic acid. In fact, butyric acid (Fig.
4c) as the sodium salt was the first compound reported
to inhibit histone deacetylation as early as 1978 [55]. As
butyric acid is rapidly excreted in minutes, the prodrug
Pivanex was developed and reached Phase II clinical tri-
als [56]. The HDAC inhibitory activity of butyric acid
sparked an interest in other short chain carboxylic acids
particularly phenylbutyric acid and valproic acid (VPA),
previously approved drugs for treating urea cycle disor-
ders [57] and epilepsy [58] respectively. Although the
level of activity is modest (micromolar IC50 against the
enzyme compared with the nanomolar potency of romi-
depsin, second-generation hydroxamic acids, and benza-
mides), their past history and knowledge of human
pharmacokinetics have facilitated drug repositioning and
their re-examination as anticancer agents in clinical tri-
als [59] or in spinal muscular atrophy (Clinical Trial
NCT00227266). While the carboxylic acid family of
HDAC inhibitors has not resulted in an approval to date,
these compounds are widely used as tool compounds in
biological studies.
To summarise, the second wave of epigenetic small-
molecule modulators involved analogue-based drug
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Fig. 4 Second-generation HDAC inhibitors. a Examples of hydroxamic acid, including belinostat (compound 16), dacinostat (compound 17), panobinostat
(compound 18), CUDC-101 (compound 19), quisinostat (compound 20), and tefinostat (compound 21). b Benzamide HDAC inhibitors that have reached clinical
development, including tacedinaline (compound 22), entinostat (compound 23), mocetinostat (compound 24), and chidamide (compound 25). c Carboxylic
acid HDAC inhibitors, including butyric acid (compound 26), pivanex (compound 27), phenylbutyric acid (compound 28), and valproic acid (compound 29)
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discovery. Taking advantage of the known leads for
DNMT and HDAC inhibition, drug discovery projects in
biotech and big pharma have culminated in more than 20
clinical candidates. At the moment, this has yielded three
approvals for HDAC inhibitors in belinostat, panobinostat,
and chidamide. A particularly exciting development was
the potential to widen the applications of HDAC inhibi-
tors by the evaluation of second-generation compounds in
non-haematological cancers. As single agents, however,
these molecules disclosed limited effectiveness. Nonethe-
less, the combination of HDACi and DNMTi was demon-
strated to be beneficial in patients harbouring solid
tumours, namely, advanced breast cancer and metastatic
lung cancer [60, 61]. Furthermore, the usage of epigenetic
therapy in combination with chemotherapeutics of a non-
epigenetic nature had been studied in early phase clinical
trials for colorectal, cervical, ovarian, and pancreatic
cancer [62]. Currently, the combination of epidrugs and
immunotherapy is also disclosing promising results in
cancer patients’ treatment, including those with colorectal,
non-small cell lung, and kidney cancers [62, 63]. Apart
from cancer, and as previously explained for vorinostat,
the use of panobinostat, chidamide, and romidepsin
are under Phase I/II clinical trials for the reactivation
of latent HIV-1 latency (Clinical Trials NCT01680094;
NCT02513901 and NCT01933594).
The third wave of epigenetic drug discovery: new
dreams, new realities
Since the last decade, the concept of epigenetic therapy
has become a reality with the approval of seven small-
molecule drugs that inhibit DNMTs and HDACs (Table
2). These success stories have validated the hypothesis
that it is possible to regulate an epigenetic process for
the treatment of disease and that a therapeutic window
can be achieved clinically for this new class of drugs.
The race is now on to extend these discoveries to other
epigenetic writer and eraser targets and even epigenetic
readers are targets for small-molecule inhibition. For
three of these in particular, as described below, signifi-
cant progress has been made and compounds are cur-
rently in clinical development.
Histone methyltransferase inhibitors
Lysine histone methyltransferases (KMTs) are the en-
zymes that post-translationally add one to three methyl
groups to lysine residues in proteins. Whereas DNA
cytosine methylation and histone deacetylation have a
repressive effect, lysine methylation can either activate
or silence gene transcription depending on the specific
lysine residue involved [64]. The human KMTs are
nearly 100 in number and use SAM as the methyl donor.
The natural product sinefungin (Fig. 5) reversibly com-
petes with SAM for its binding site and therefore is a
non-selective inhibitor of all SAM utilising enzymes
[65]. The breakthrough in KMT drug discovery has
hinged on the ability to design potent SAM-mimetics
that are selective by taking advantage of differences in
the cofactor binding pocket [65]. Epizyme’s pinometo-
stat, a highly selective DOT1L inhibitor, was the first
KMT inhibitor to enter Phase I clinical trials for the
treatment of leukaemia [66]. Then, GlaxoSmithKline and
Epizyme have independently employed a pyridone scaf-
fold for the selective EZH2 inhibitors GSK2816126
(NCT02082977) and tazemetostat (NCT01897571), re-
spectively, that are undergoing Phase II trials for B cell
lymphoma [67]. Both DOT1L and EZH2 inhibitors have
exciting prospects for personalised medicine [64, 68].
Among the arginine methyltransferase inhibitors, the
first to enter clinical trials is GSK3326595 (formerly
EPZ015938) directed against PRMT5 [69]. PRMT5 over-
expression is observed in cell lines and primary patient
samples derived from a number of cancers, and clinical
trials have started in 2016 in non-Hodgkin lymphoma
and solid tumours [69]. In addition, PRMT5 inhibitor
JNJ-64619178 (Clinical Trial NCT03573310) as well as
PRMT1 inhibitor GSK3368715 (formerly EPZ019997)
(Clinical Trial NCT03666988) have now entered clinical
trials.
Lysine demethylase inhibitors
Lysine methylation is reversed by the lysine demethylase
enzymes (KDMs) that are subdivided into two families
based on their catalytic mechanism [70]. The larger
Jumonji C (JmjC) demethylases comprise about twenty
human enzymes classified as KDM2-7. These are part of
the 2-oxoglutarate and iron (II)-dependent dioxygenase
family and are capable of demethylating mono-, di-, and
trimethylated lysine residues. Although there are inter-
esting links between JmjC demethylases and human
disease, at present, inhibitors of the enzymes are at the
stage of chemical probe development [70]. The second
family KDM1 contains the enzyme lysine-specific
demethylase that exists as two isoforms LSD1 and LSD2
(also known as KDM1A and KDM1B), which are mono-
and dimethyl-lysine demethylases. The LSD enzymes are
homologous to monoamine oxidases (MAOs) in their
mechanism and similarly use FAD as the cofactor to ef-
fect oxidative cleavage of the methyl group. LSD inhibi-
tor design has greatly benefited from this homology as
old MAO inhibitor drugs have been repurposed as
demethylase inhibitors [70]. The most successful ex-
ample is tranylcypromine (Fig. 6), an approved MAO in-
hibitor initially used as an antidepressant [71]. In AML
that is resistant to chemotherapy with all-trans retinoic
acid (ATRA), LSD1 inhibition by tranylcypromine re-
stores sensitivity to ATRA [72]. As a result, combination
therapy with the two drugs is being evaluated in clinical
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trials (Clinical Trial NCT02273102). Since tranylcypro-
mine is a modest LSD1 inhibitor (IC50 ~ 20 μM), many
analogues have been reported with a view to improving
its activity and reducing off-target effects against other
FAD-containing enzymes. Among these second-
generation compounds, Oryzon and GlaxoSmithKline
have disclosed the structures of their respective clin-
ical candidates ORY-1001 and GSK2879552 in Phase
I/II trials [73]. In AML, LSD1’s function as a H3K4
demethylase leads to the maintenance of stemness
hence supporting the idea of therapeutic intervention
through this target [74].
Fig. 5 Examples of KMT inhibitors including the clinical candidates sinefungin (compound 30), pinometostat (compound 31), GSK2816126 (compound 32),
tazemetostat (compound 33), compound GSK3326595 (compound 34), JNJ-64619178 (compound 35), and GSK3368715 (compound 36)
Fig. 6 The mechanism of action of tranylcypromine and tranylcypromine analogues in clinical trials as LSD1 inhibitors. The monoamine oxidase
inhibitor tranylcypromine (compound 37) binds as a suicide substrate in the MAO or LSD active site and then undergoes strain-induced ring
opening to give a reactive radical cation (compound 38). This reactive intermediate covalently adds to the FAD cofactor thereby irreversibly
inhibiting the enzyme. Tranylcypromine analogues are being developed to improve inhibition, including ORY-1001 (compound 39), GSK2879552
(compound 40), and 4SC-202 (compound 41)
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In the quest of new inhibitors scaffolds, of note is the
design and selection of cyclic peptides to target KDMs
with high selectivity (such as CP2 for KDM4A-C) [75].
Bromodomains
The drug discovery targets discussed above are either
writers (DNMTs and KMTs that methylate DNA and
histones respectively) or erasers (HDACs and KDMs
that deacetylate and demethylate histones respectively).
The first epigenetic readers to have a significant impact
on drug discovery are the bromodomains [76]. This fam-
ily of protein recognition domains for acetyl-lysine resi-
dues consists of 61 human members. The acetyl-lysine
binding region is hydrophobic in nature and can be oc-
cupied by small-molecule ligands. Within the bromodo-
mains, the BET (bromo and extra terminal) family
comprising BRD2, BRD3, BRD4, and BRDT has been a
predominant focus for drug discovery [76] because of
their implication in cancer. As an example, BRD4 pro-
motes the expression of oncogenes, while the transloca-
tion of BRD3 or BRD4 to the NUT oncogene leads to its
constitutive activity and is the cause of NUT midline
carcinoma (NMC) [77]. The first small-molecule ligands
for bromodomains were discovered serendipitously in
pharmaceutical companies through cell-based assays
without knowledge of their mechanism of action. At
GlaxoSmithKline, for example, an assay for upregulation
of ApoA1 transcription identified a series of hits that
were then shown by proteomic studies to be potent li-
gands for the BET bromodomains [78]. Further opti-
misation produced I-BET762 (Fig. 7), a nanomolar BET
ligand that is in Phase I/II trials for NMC and haemato-
logical cancers [79]. Due to their implication in multiple
biological pathways, BET inhibitors are also being
explored in other diseases, including diabetes or reacti-
vation of latent HIV-1 in human cells [79]. Parallel in-
vestigations at other pharmaceutical companies with the
benzodiazepine scaffold have led to clinical candidates
including Constellation’s CPI-0610 and OncoEthix’s
OTX015 [80]. While these compounds are being investi-
gated in cancer, Resverlogix’s RVX-208 was discovered
through phenotypic screening in an atherosclerosis
programme [81]. The compound has recently completed
Phase IIb trials that demonstrated increased levels of
ApoA1 and high-density lipoprotein (HDL) in patients
(Clinical Trial NCT02586155).
To summarise, the third wave of epigenetic drug dis-
covery has witnessed rapid progress with three new tar-
gets: the KMTs, KDMs, and bromodomains. The speed
from bench to bedside has been breath-taking given that
the bromodomain was identified as an acetyl-lysine
binding unit only in 1999, EZH2 as the H3K27 methyl-
ase in 2002 and LSD1 as a KDM in 2004. In just over a
decade, multiple small-molecules for these targets have
advanced to clinical trials and it is highly likely that one
or more will receive clinical approval in the near future.
Although the process of drug discovery has followed the
modern paradigm of target validation followed by se-
quential in vitro and in vivo proof of concept, the role of
phenotypic observation should not be forgotten. The
bromodomain efforts were accelerated through reporter-
based phenotypic assays that led to the discovery of
high-affinity ligands whose mechanism of action was
only elucidated later. For LSD1, the most promising lead
has been tranylcypromine, an old drug with a 50-year
history of use as an antidepressant through a non-
epigenetic target.
The fourth wave of epigenetic drug discovery:
crystal ball gazing
The developments in epigenetic drug discovery [64, 82, 83],
together with the growing insights in the importance of epi-
genetic mutations in diseases [5, 84–86] and consequent bio-
marker discovery [86], definitely marks epigenetics as an
exciting field of research with promising clinical implications.
Indeed, the speed of developments in drug design indicates
the huge demand for this novel avenue to be fully exploited
in order to combat diseases. In this section, we discuss vari-
ous challenges and opportunities for the implementation on
epigenetic drug in clinical use, including aspects as target se-
lection, chemistry-associated concerns, in vivo biology, or
clinical considerations (Fig. 8).
Selection of the most appropriate druggable target
with functional impact on the disease is undoubtedly a
high relevant consideration. Next to rational chemical
medicinal engineering approaches, biological approaches
(protein complexes or cells) are essential to identify the
functional effects of inhibiting particular enzymes or
even isoforms [87, 88]. The EU H2020 COST Action
consortium CM1406 (www.EpiChemBio.eu) brought to-
gether scientists from the different fields (chemistry,
biology, medicine) to address such complex issues. The
recently introduced CRISPR/Cas approach has raised ex-
ponential interest as a tool to correct genetic mutations
but also offers powerful possibilities to inactivate any
given gene [89]. Moreover, if loss-of-function is caused
by epigenetic silencing of expression, CRISPR/Cas can
be repurposed to target effectors to that genomic locus
to re-express the silenced gene. This latter application of
CRISPR/Cas is achieved by mutating the nuclease activ-
ity of the Cas protein (resulting in a dead Cas (dCas))
[89]. dCas is still being recruited to the genomic site of
interest via single guide RNAs, and dCas can thus be
used to shuttle any fused protein to this location. If the
catalytic domain of an epigenetic enzyme is fused to
dCas, the system will result in rewriting of the epigenetic
signature at this particular location (epigenetic editing)
[89]. Furthermore, for non-cancerous diseases where cell
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death is not the final goal, sustainability of the effect is
important and can be achieved using epigenetic editing.
Interestingly, sustained re-expression of epigenetically si-
lenced genes has been shown for various genes, includ-
ing tumour suppressor genes [90].
Although an epigenetic target has been identified for a
specific disease, several challenges need to be overcome
for a successful epigenetic drug design, including en-
zyme isoform selectivity, the selectivity for histone’s ly-
sines and arginines vs. non-histone substrates, the
design of dual inhibitors, how to use the epigenetic
drugs in combinations, and the fact that epigenetic en-
zymes often work in multimeric complexes, which [91,
92] complicates the translation of in vitro potency to
in vivo efficacy.
Regarding the chromatin complexes, it must be con-
sidered that there is an interplay among epigenetic fac-
tors for controlling gene expression. It has been
described that targeting histone modifiers, such as the
most common inhibitors of histone deacetylases (vorino-
stat, sodium butyrate, or trichostatine A), can result in
changes on methylation of histones [93] and also alter
the binding of chromatin remodelling factors at the
same locus. HDAC inhibition may also alter the CpG
methylation of specific promoters by affecting the activ-
ity of DNMTs [94]. One of the reasons for this inter-
action is that epigenetic modifiers work in complexes
with other chromatin-related proteins [87]. Thus, the
intervention on one partner can induce unforeseen ef-
fects on the other partners of the complex. It is really
Fig. 7 Examples of bromodomain ligands in clinical development, including I-BET762 (compound 42), CPI-0610 (compound 43), OTX015 (compound
44), and RVX-280 (compound 45)
Fig. 8 Challenges and opportunities for epigenetic drug discovery
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important to consider such cross-talk for in vitro genetic
studies or assays for compound screening because effect-
ively targeting a specific epigenetic enzyme in in vitro
situations may not be effective in the cellular context.
In addition, several actual epidrugs do not show full
selectivity. In one hand, isoform selectivity is not pos-
sible for several epidrugs. Development of isoform-
selective inhibitors will be very useful because it can help
to understand the role of each isoform. For example, in
the case of the DNMTs, it would be very useful therapy-
wise to know which DNMT is involved in which cancer
or stage: is DNMT1 the best target or rather DNMT3A
or 3B? On the other hand, multiple epigenetic enzymes
from the same complex can be targeted. As an example,
HDAC inhibitors can also repress the histone methyl-
transferase JARID1 [93], even if a lot of efforts are dedi-
cated to designing specific inhibitors [95–98]. The
development of multitarget inhibitors is in part address-
ing the latter point. It is based on the development of
dual inhibitors, i.e. with two active motives targeting dif-
ferent epigenetic protein within the same molecule,
which advantageously ensure simultaneous effect in cells
of active entities, shorten clinical development, and min-
imise resistance phenomena. Thus, it appears to be of
major interest to study the impact of hybrid inhibitors to
improve the therapeutic management of cancer [22, 99].
An interesting example is the dual targeting of DNMT
and G9A that induced prolonged survival in AML, ALL,
and DLBCL xenogeneic models [100].
Another important issue is histone vs. non-histone se-
lectivity. Substrate selectivity of epigenetic enzymes has
been taken into consideration for a long time and evi-
dence exist that substrates of epigenetic enzymes are not
limited to canonical chromatin proteins [68, 92]. For ex-
ample, the catalytic activity of the HAT p300/CBP in-
cludes acetylation at lysine residues of histone H3 and
H4 but also acetylation of the oncogene p53 [91, 101].
Similarly, the histone HMT SMYD2 shows a strong pref-
erence for p53 peptide over histones as substrates for
methylation [102]. Again, using in vitro assays based on
nucleosomes substrates may not fully recapitulate the ef-
fect of the drug in a cellular context. In any case, this
point should be considered when testing the off-targets
of the compounds in cells.
This relates to the challenge of designing screening as-
says that takes into account the biological complexes of
the enzyme and the structure of the chromatin. The ex-
pansion of High-Content Screening can address in part
the challenge together with phenotypic screening that, as
described above, has been important for the discovery of
certain epigenetic drug. In parallel, the hit rates of the
screening assays are low [103], suggesting that the design
of focused chemical libraries for the epigenetic enzyme
pockets that accommodate charged amino acid residues
and hydrophilic molecules might increase the efficiency
of lead discovery [104]. Fragment-based approaches are
also explored in particular for protein targets that are
poorly druggable by small-molecules. Cyclic peptides
and stapled peptides are interesting chemical strategies
to be further explored, together with the promising
PROTAC strategy that induces the degradation of the
protein targeted by the drug through E3 ligase recruit-
ment and protease degradation [105, 106] Another chal-
lenge is the pharmacology of the compounds: the dose
to be used (low doses have better effect for DNMT in-
hibitor s[107], or for how long to treat. The epigenetic
reprogramming takes time, especially when the drug tar-
get are the ‘writers’ proteins: the epigenetic mark will be
lost by passive demethylation or deacetylation [103,
108]. Does this mean that patients need to be treated for
life? The recent clinical trials for the treatment of MLLr
leukaemia with the inhibitor of DOT1L EPZ5676 are
starting to address this question. Certainly, combination
therapies, an epigenetic reprogramming followed by
chemotherapy or immune-therapy, are promising strat-
egies to eradicate cancer [109], but how to use the drugs
in combination is to be optimised, e.g. first epigenetically
reprogram and then treat with the immune or conven-
tional therapy or administer both drugs simultaneously
and so on.
It must be not forgotten that epigenetic factors are not
only controlling gene expression in cis, that is to say,
regulating directly the occupancy of the transcription
factor machinery at specific loci. Epigenetic modifiers
are also involved in the formation and maintenance of
high-order chromatin structures regulating long-
distance interactions [110]. The study of the role of
ncRNAs in the regulation of the high-order chromatin
structure is rapidly increasing and supporting the epi-
genetic regulation of genomic sequences in trans [111,
112].
From a clinical point of view, reprogramming the epi-
genetic landscape to combat chronic diseases requires a
long-lasting effect. In this respect, inhibition of one epi-
genetic enzyme is not expected to result in sustained ef-
fects. Using epigenetic editing, many different epigenetic
writers or erasers can be simultaneously targeted to a
locus of interest to rewrite the epigenetic signature in
such a way that the effects might be mitotically stable
for many cell divisions [90, 113].
Although several on-going clinical trials exist on a
wide range of tumoural and non-tumoural diseases, so
far the use of epigenetic drugs in clinical practice is
mostly limited to haematological malignancies [114,
115]. The potential of epigenetic drugs is extending to
other pathologies, from infectious diseases to brain dis-
eases, cardiovascular and metabolic disorders [5, 116].
This is very promising and we expect to observe
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interesting results in the following years. However, de-
velopment of clinical trials requires the identification of
biomarkers that can predict the drug response and avoid
unnecessary side effects in patients with non-sensitive
tumours. Both epigenetic mutations (i.e. promoter
hypermethylation of tumour suppressor genes) and
genetic mutations of epigenetic enzymes (loss or gain of
function) can be used as predictors of response to
chemotherapy in several cancer types [117]. For ex-
ample, the epigenetic-associated silencing of MGMT is
used as biomarker to predict the response to temozolo-
mide treatment in glioblastoma patients [118].
Conclusions
Current developments shed light on the importance of
combining epidrugs (and also epidrugs with non-
epigenetic therapeutic agents) that help to define im-
proved policies for cancer treatment and non-cancer dis-
eases. Validation of (epigenetics) biomarkers will assist
in diagnosis, prediction to drug response and eventually
identifying the responsive patients. All in all, researchers
from various disciplines (chemists, biologists, clinicians)
need to work together to optimise the drug engineering,
read-out assays and clinical trial design.
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